Select a medication above to begin.
Imsidolimab
imsidolimab
Adult Dosing .
Dosage forms: INJ
Investigational New Drug (IND)
- [pending FDA approval]
generalized pustular psoriasis
- [indication/pt population pending FDA approval]
- Info: binds to IL-36 receptor and inhibits IL-36 cytokine-induced activation of pro-inflammatory and pro-fibrotic pathways (monoclonal antibody)
Peds Dosing .
- Dosage forms: --
Investigational New Drug (IND)
- [pending FDA approval]
- Info: not anticipated to be applicable to Peds population